Ponvory

Chemical Nameponesimod
Dosage FormTablet (oral; 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg)
Drug ClassModulators
SystemNervous
CompanyJanssen Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Last updated on 4/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ponvory (ponesimod) Prescribing Information.2021Janssen Pharmaceuticals, Inc. Titusville, NJ
Document TitleYearSource
Assessment report: Ponvory. 2021EMA